Skip to content
About LineaRx
Leadership Team
Investor Info
Linea DNA Platform
Applications
News
Events
Resources
Let’s Connect
About
About LineaRx
Leadership Team
Investor Info
Platform
Applications
News
Events
Resources
Let’s Connect
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
December 18, 2024
Read More
email
Research Publication Demonstrates Utility of APDN’s LinearDNA™ in Non-Viral CAR T Manufacturing
November 9, 2021
Read More
email
Recent Press Releases
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
LineaRx Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
Applied DNA and Alphazyme Conclude Linea™ RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea™ IVT Platform Economics
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea™ IVT Platform
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNA™ for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
